Rational Drug Design Approach for Overcoming Drug Resistance: Application to Pyrimethamine Resistance in Malaria

James H. McKie,† Kenneth T. Douglas,*,† Cecil Chan,† Simon A. Roser,† Robert Yates,† Martin Read,‡ John E. Hyde,‡ Michael J. Dascombe,§ Yongyuth Yuthavong, and Worachart Sirawaraporn

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, U.K., Department of Biomolecular Sciences, UMIST, Manchester M60 1QD, U.K., School of Biological Sciences, University of Manchester, Manchester M13 9PT, U.K., National Science and Technology Development Agency, Rama VI Road, Bangkok 10400, Thailand, and Department of Biochemistry, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand

Received December 15, 1997

Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase–thymidylate synthase (DHFR–TS). Resistance in the most important human parasite, Plasmodium falciparum, initially results from an S108N mutation in the DHFR domain, with additional mutation (most commonly C59R or N51I or both) imparting much greater resistance. From a homology model of the 3-D structure of DHFR–TS, rational drug design techniques have been used to design and subsequently synthesize inhibitors able to overcome malarial pyrimethamine resistance. Compared to pyrimethamine (Ki 1.5 nM) with purified recombinant DHFR from P. falciparum, the Ki value of the m-methoxy analogue of pyrimethamine was 1.07 nM, but against the DHFR bearing the double mutation (C59R + S108N), the Ki values for pyrimethamine and the m-methoxy analogue were 71.7 and 14.0 nM, respectively. The m-chloro analogue of pyrimethamine was a stronger inhibitor of both wild-type DHFR (with Ki 0.30 nM) and the doubly mutant (C59R + S108N) purified enzyme (with Ki 2.40 nM). Growth of parasite cultures of P. falciparum in vitro was also strongly inhibited by these compounds with 50% inhibition of growth occurring at 3.7 μM for the m-methoxy and 0.6 μM for the m-chloro compounds with the K1 parasite line bearing the double mutation (S108N + C59R), compared to 10.2 μM for pyrimethamine. These inhibitors were also found in preliminary studies to retain antimalarial activity in vivo in P. berghei-infected mice.

Introduction

Pyrimethamine (Chart 1) has been employed for many years against malaria, initially on its own but subsequently in combinations such as Maloprim (pyrimethamine–dapsone) and Fansidar (pyrimethamine–sulfadoxine), the latter a widely used formulation for the treatment of chloroquine-resistant malaria. Pyronaridine, a new Chinese drug, has been tested against malaria in combination with pyrimethamine. Pyrimethamine has also been used recently against toxoplasmosis encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients, and atovaquone has been tested against murine toxoplasmosis in combination with pyrimethamine. Pyrimethamine also has antibacterial value. Dapsone–pyrimethamine may prevent mycobacterial disease (Mycobacterium tuberculosis, Mycobacterium avium) in immunosuppressed patients infected with HIV.

With very few safe, effective, and cheap antimalarial drugs, the problem of parasite resistance has enormous economic and social consequences, particularly in Africa, where malaria causes ca. 2 million deaths per year and very high levels of morbidity. As a result, ways are being sought to impede the onset and spread of drug resistance. Resistance to pyrimethamine, first reported shortly after its introduction in the 1950s, is now widespread worldwide. To delay (but not overcome) further malarial resistance to inhibitors such as pyrimethamine, combinations such as those above with sulfonamides or sulfones have been in use for some years. Fansidar, for instance, is currently the first-line drug of choice in a
number of African countries, but resistance to both components of this combination is an increasing problem.

Pyrimethamine inhibits dihydrofolate reductase–thymidylate synthase (DHFR–TS) in the folate biosynthetic pathway, and resistance to it arises from mutation in the dhfr-ts gene. Studies on long-term continuous culture isolates have shown that in the lethal species of the human malaria parasite, *Plasmodium falciparum*, resistance results in the first instance from an S108N mutation in the DHFR domain, but double and triple mutations impart much higher levels of resistance.\(^7\)-\(^{11}\) Resistance to pyrimethamine and the related antifolate cycloguanil has recently been studied in a wide range of field samples of *P. falciparum*,\(^1\)\(^2\)-\(^4\) as well as in the long-term continuous culture isolates referred to above. The most common resistant strains showed the double mutations S108N + C59R or S108N + N51I or the triple combination of these modifications. Additionally an I164L mutation has been seen in some cases, imparting very high level resistance to both pyrimethamine and cycloguanil. The association of antifolate resistance with mutations in the DHFR domain has been directly demonstrated in vitro via mutagenesis of synthetic *P. falciparum* dhfr genes,\(^1\)\(^5\)-\(^1\)\(^6\) as well as by transformation of sensitive parasites with recombinant gene constructs carrying the individual mutations.\(^1\)\(^7\) Further, in multiple mutants there is evidence that these point mutations interact with one another in a cooperative manner.\(^1\)\(^8\) There has been a recent report of the use of computational docking of commercially available compounds to a homology-built molecular model of the DHFR domain of the DHFR–TS of *P. falciparum*.\(^1\)\(^9\) This provided two new families of inhibitors, in which the best \(K_i\) achieved was 0.54 \(\mu\)M against recombinant *P. falciparum* DHFR domain.

One of us recently modeled the three-dimensional structure for DHFR–TS from *Leishmania* major,\(^2\)\(^0\) and although this is now superseded by an X-ray diffraction study of this enzyme,\(^2\)\(^1\) we did not have access to the coordinates at the time of this study. Even using the crude approximation of the *L. major* DHFR–TS model (as a basis for *P. falciparum* DHFR–TS), we were able to design inhibitors with the potential to overcome malarial pyrimethamine resistance. The molecular model indicated for the S108N mutation that, if the active-site structure of *Plasmodium* DHFR–TS was similar to that of *Leishmania*, there would be a steric clash of the protein with the p-Cl atom of pyrimethamine. It was proposed, and a molecular graphics picture showed\(^2\)\(^0\) that a suitable substituent in the adjacent meta position would avoid this clash and permit an additional interaction with the enzyme. To test this we synthesized two analogues of pyrimethamine, viz., CC83 and S03 (Chart 1), and compared them to the parent compound in three independent assays, using purified recombinant enzymes, in vitro parasite cultures, and in vivo drug challenge.

**Results and Discussion**

CC83 and S03 were found to be strong inhibitors of DHFRs from *P. falciparum*, plots being shown in Figure 1. The kinetics and inhibition data for DHFR from wild-type (WT) and C59R + S108N double mutant are summarized in Table 1. As reported\(^1\)\(^8\) for purified DHFR–TS (Table 1), C59R–S108N mutations were found to increase \(K_i\) for Pyr and Cyc by 48- and 32-fold, respectively, compared to WT. CC83 was found to be 50% more effective as Pyr against WT DHFR–TS, while S03 inhibited WT enzyme 3-fold better than CC83 and 5 and 9 times better than Pyr and Cyc, respectively.
Drug Design Approach for Overcoming Drug Resistance

Table 1. Inhibition of Recombinant WT and Mutant (C59R + S108N) P. falciparum DHFR–TS by Pyrimethamine (Pyr), Cycloguanil (Cyc), CC83, and S03

<table>
<thead>
<tr>
<th>Parameter</th>
<th>WT enzyme</th>
<th>double-mutant (C59R + S108N) (mutant/WT)</th>
<th>ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>substrates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H$_2$Folate, $K_m$, $\mu$M</td>
<td>12.9 ± 4.9</td>
<td>23.7 ± 9.3</td>
<td>1.83</td>
</tr>
<tr>
<td>NADPH, $K_m$, $\mu$M</td>
<td>4.7 ± 1.3</td>
<td>14.5 ± 0.8</td>
<td>3.09</td>
</tr>
<tr>
<td>inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyr, $K_i$, nM</td>
<td>1.5 ± 0.2</td>
<td>71.7 ± 2.9</td>
<td>47.8</td>
</tr>
<tr>
<td>Cyc, $K_i$, nM</td>
<td>2.6 ± 0.3</td>
<td>82.1 ± 3.7</td>
<td>31.5</td>
</tr>
<tr>
<td>CC83, $K_i$, nM</td>
<td>1.07 ± 0.10</td>
<td>14.0 ± 2.6</td>
<td>13.1</td>
</tr>
<tr>
<td>S03, $K_i$, nM</td>
<td>0.30 ± 0.03</td>
<td>2.40 ± 0.26</td>
<td>8.0</td>
</tr>
</tbody>
</table>

* Data from ref 18.  
* From duplicate experiments.

Table 2. Inhibition of in Vitro P. falciparum Parasite Cultures by Pyrimethamine (Pyr), Cyc, CC83, and S03

<table>
<thead>
<tr>
<th>Parasite line (IC$_{50}$, $\mu$M)</th>
<th>HB3 (S108N)</th>
<th>K1 (S108N + C59R)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyr $^a$</td>
<td>1.2</td>
<td>10.2</td>
</tr>
<tr>
<td>CC83</td>
<td>0.2</td>
<td>3.7</td>
</tr>
<tr>
<td>S03</td>
<td>0.04</td>
<td>0.6</td>
</tr>
</tbody>
</table>

* IC$_{50}$ values were defined as the concentration of inhibitor at which parasite growth was reduced to one-half that of mock-treated controls, as measured by parasitemia levels. Average of duplicate determinations.

The strong activity of CC83 and S03 against recombinant DHFR domain of malarial bifunctional DHFR–TS supports the applicability of even the admittedly crude model of the active site used. While modeling predicted that either CC83 or S03 would inhibit S108N mutant DHFR, it did not indicate that S03 would be stronger than CC83 against the double-mutant DHFR (S108N + C59R). This may be related to the cooperativity of interaction of the point-mutation sites in multiple mutants of P. falciparum DHFR. Cooperative interactions within the receptor target site clearly must be addressed in general, not just for DHFR, for rational drug design based on proteins as drug targets to be predictive. Other mutations, also known to be involved in resistance, should ideally be included in such analysis.

Rational design methods have only rarely been used to reach testable molecules in parasitology. The present case provides an example of computer-aided drug re-engineering to overcome drug resistance. While current rational drug design methods do not explicitly consider pharmacokinetics or pharmacodynamics, the minimal nature of the physicochemical change relative to pyrimethamine needed for S03 to overcome resistance augurs well for these aspects.

**Experimental Section**

For synthesis anhydrous reactants, and dry solvents were used. Aluminum oxide (active neutral, Brockmann Grade 1) was purchased from BDH Chemicals Ltd. TLC was carried out on aluminium and silica plates. Spots were made visible by UV light or exposure to iodine vapor. Melting points, taken on a Gallenkamp apparatus with digital thermometer, are uncorrected. NMR proton spectra were recorded on a J EMX 270 spectrometer operating at 270 MHz. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane or to the 7.25 ppm residual chloroform peak for 1H NMR spectra. All mass spectra were taken by means of a Kratos MS20 instrument coupled to a DSS5 data system for precise mass determination. Elemental analyses were performed on an EA 1106 elemental analyzer (Carlo Erba Instruments) in the Department of Chemistry of the University of Manchester.

**Synthesis.** CC83 and S03 were prepared by literature methods.24-26 S03 was isolated as a white powder, which did not need recrystallization: mp 215-220 °C (uncorrected); TLC R$_f$ 0.51 in petroleum ether/ethyl acetate (8:2, v/v); NMR (CD$_3$J$_{1,2}$, 270 MHz) $\delta$ 8.32 (1H, s, ArH), 7.40 (2H, m, ArH), 7.2 (2H, m, ArH), 5.9 (2H, brs, NH$_2$) 5.6 (2H, brs, NH$_2$), 2.1 (2H, q, CH$_2$), 1.0 (3H, t, CH$_3$); IR (cm$^{-1}$), 3310 (NH stretch); 1600 (C=O stretch); MS calculated for C$_{12}$H$_{13}$ClN$_4$ 248.7163, found 248.0824. Anal. (C$_{12}$H$_{13}$ClN$_4$) C, H, N.

CC83 was isolated as a white powder which did not need recrystallization: mp 224-244 °C; NMR (DMSO-d$_6$, 270 MHz) $\delta$ 7.39 (1H, m, ArH), 6.97 (1H, m, ArH), 6.77 (2H, m, ArH), 5.88 (2H, brs, NH$_2$), 5.63 (2H, brs, NH$_2$), 3.87 (3H, s, OCH$_3$), 2.17 (2H, q, CH$_2$), 1.08 (3H, t, CH$_3$); IR (cm$^{-1}$), 3320 (NH stretch); MS calculated for C$_{12}$H$_{13}$ClN$_4$ 248.2979, found 248.1329. Anal. (C$_{12}$H$_{13}$ClN$_4$) C, H, N.

**Enzyme Assays.** The compounds were tested for the ability to inhibit DHFR activity and parasite growth in culture. The synthetic genes encoding WT and C59R + S108N mutant DHFR domain of bifunctional DHFR–TS were used, and the DHFR activity was determined spectrophotometrically as described.13 The assay reaction (1 mL) contained 100 $\mu$L each of dihydrofolate and NADPH, 50 mM TES, pH 7.0, 75 mM 2-mercaptoethanol, 1 mg/mL bovine serum albumin, varying concentration of inhibitor, and appropriate amount of enzyme. For inhibition studies, CC83 and S03 were initially dissolved in HPLC-grade DMSO and subsequently added to the assay
reaction (final concentrations, 0–1 μM). The reactions were initiated with purified, recombinant enzymes (∼0.6–1 nM). The Kᵣ values were determined by fitting the data to IC₅₀ = Kᵣ + [S]Kₘ, where Kₘ is the Michaelis constant for dihydrofolate, [S] is the concentration of dihydrofolate, and IC₅₀ is the concentration of inhibitor giving 50% inhibition under the assay conditions described above.

In Vitro parasite cultures

In vitro parasite cultures (initial parasitemias, 0.5%) were maintained as described but in microtiter plates. Growth, monitored as percentage of erythrocytes containing Leishmania after inoculation, and parasitemia was assessed from blood smears as the percentage of erythrocytes containing Leishmania-positive bodies by light microscopy. The general autonomic and behavioral states of the mice were visually observed throughout the screening period.

Acknowledgment.

We are grateful for partial support from the Wellcome Trust (K.T.D., J.H.M., J.E.H.), the World Health Organization (C.C.), and the MRC (M.R.) and also thank Rachada Sirawaraporn and Suganya Yongkiettrakul for excellent assistance.

References